Overview

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRT

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determinate the effectiveness, safety and tolerability (how well the body accepts the drug) of an investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) called TMC125.

Phase:

Phase 2

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Etravirine